Copeland Capital Management’s LeMaitre Vascular LMAT Stock Holding History

Copeland Capital Management’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$80.6M	Sell	839,463 -31,229	-4%	-$3.2M	1.65%	11
2026 Q1	$95.1M	Sell	870,692 -18,285	-2%	-$1.74M	2.11%	3
2025 Q4	$72.1M	Sell	888,977 -51,351	-5%	-$4.42M	1.61%	11
2025 Q3	$82.3M	Sell	940,328 -49,709	-5%	-$4.44M	1.71%	5
2025 Q2	$82.2M	Sell	990,037 -88,686	-8%	-$7.41M	1.69%	6
2025 Q1	$90.5M	Sell	1,078,723 -93,292	-8%	-$8.68M	1.81%	7
2024 Q4	$108M	Buy	1,172,015 +8,623	+0.7%	+$829K	2.01%	4
2024 Q3	$108M	Buy	1,163,392 +11,318	+1%	+$981K	1.88%	4
2024 Q2	$94.8M	Sell	1,152,074 -138,819	-11%	-$10.2M	1.77%	8
2024 Q1	$85.7M	Buy	1,290,893 +30,932	+2%	+$1.91M	1.56%	13
2023 Q4	$71.5M	Buy	1,259,961 +28,720	+2%	+$1.5M	1.43%	20
2023 Q3	$67.1M	Buy	1,231,241 +5,515	+0.4%	+$327K	1.44%	22
2023 Q2	$82.5M	Sell	1,225,726 -139,016	-10%	-$8.48M	1.7%	7
2023 Q1	$70.2M	Buy	1,364,742 +87,264	+7%	+$4.24M	1.65%	12
2022 Q4	$58.8M	Buy	1,277,478 +53,896	+4%	+$2.52M	1.55%	16
2022 Q3	$62M	Buy	1,223,582 +11,276	+0.9%	+$563K	2.05%	4
2022 Q2	$55.2M	Sell	1,212,306 -2,699	-0.2%	-$121K	1.75%	8
2022 Q1	$56.5M	Buy	1,215,005 +9,806	+0.8%	+$439K	1.56%	13
2021 Q4	$60.5M	Buy	1,205,199 +80,112	+7%	+$4.14M	1.57%	13
2021 Q3	$59.7M	Buy	1,125,087 +62,054	+6%	+$3.5M	1.7%	5
2021 Q2	$64.9M	Buy	1,063,033 +171,708	+19%	+$9.12M	1.95%	5
2021 Q1	$43.5M	Sell	891,325 -60,170	-6%	-$2.82M	1.35%	36
2020 Q4	$38.5M	Buy	951,495 +63,577	+7%	+$2.27M	1.52%	25
2020 Q3	$28.9M	Buy	887,918 +221,953	+33%	+$6.66M	1.28%	38
2020 Q2	$17.6M	Buy	665,965 +24,917	+4%	+$651K	0.91%	48
2020 Q1	$16M	Buy	641,048 +79,975	+14%	+$2.47M	0.97%	43
2019 Q4	$20.2M	Buy	561,073 +20,588	+4%	+$710K	0.88%	47
2019 Q3	$18.5M	Buy	540,485 +152,753	+39%	+$4.88M	0.95%	42
2019 Q2	$10.8M	Buy	387,732 +209,913	+118%	+$5.83M	0.6%	59
2019 Q1	$5.51M	Buy	177,819 +177,086	+24,159%	+$4.73M	0.35%	77
2018 Q4	$17K	Buy	+733	New	+$20K	﹤0.01%	163

Other funds holding LMAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.36B AUM 17.81% 1-Year Est. Return

Copeland Capital Management's LMAT Position: Q2 2026 in Review

Copeland Capital Management reduced its LeMaitre Vascular (LMAT) stake by 3.6% in Q2 2026, selling an estimated $3.2M and leaving 839,463 shares worth $80.6M. The position accounts for 1.65% of the portfolio, ranked #11.

Copeland Capital Management first reported a position in LMAT in Q4 2018 and has held it in 31 quarters since. The position peaked at $108M in Q3 2024. 326 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.

Copeland Capital Management held 839,463 shares of LeMaitre Vascular worth $80.6M as of Q2 2026.
Copeland Capital Management sold 31,229 LeMaitre Vascular shares in Q2 2026, an estimated $3.2M.
LeMaitre Vascular made up 1.65% of Copeland Capital Management's portfolio in Q2 2026, its #11 holding.
Copeland Capital Management first reported a position in LeMaitre Vascular in Q4 2018 and has held it in 31 quarters since.
Copeland Capital Management's LeMaitre Vascular position peaked at $108M in Q3 2024.
326 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.

Based on Copeland Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.